3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled